PMS2相关Lynch综合征的癌症风险
该研究基于全球合作的大数据集,采用改良分离分析纳入284个家系共4878名一级和二级亲属,估计PMS2致病变异携带者各癌种的年龄特异性累积风险。结果显示携带者结直肠癌和子宫内膜癌风险轻度升高,至80岁累积风险分别为男性13%、女性12%和13%,其他Lynch综合征相关癌症风险未见明显升高。
要点
- PMS2携带者至80岁结直肠癌累积风险男性13%、女性12%,子宫内膜癌13%。
- 卵巢、胃、肝胆、膀胱、肾、脑、乳腺、前列腺及小肠癌风险未见明显升高。
- PMS2特异性筛查方案可仅限于结肠镜检查。
核心结论
- 杂合PMS2致病变异携带者结直肠癌和子宫内膜癌风险轻度升高,其他Lynch综合征相关癌症风险未见升高。
研究设计与样本
- 采用改良分离分析,纳入基因分型和非基因分型亲属,并对确认方式做偏倚校正。
- 共纳入284个家系、4878名一级和二级家庭成员。
主要发现
- PMS2携带者至80岁结直肠癌累积风险男性13%(95%CI 7.9%–22%),女性12%(95%CI 6.7%–21%),一般人群分别为6.6%和4.7%。
- 子宫内膜癌至80岁累积风险13%(95%CI 7.0%–24%),一般人群为2.4%。
- 卵巢、胃、肝胆、膀胱、肾、脑、乳腺、前列腺及小肠癌未见明确风险升高证据。
关键数值与推荐
- PMS2携带者结直肠癌至80岁累积风险男性13%(95%CI 7.9%–22%)、女性12%(95%CI 6.7%–21%)。
- 子宫内膜癌至80岁累积风险13%(95%CI 7.0%–24%)。
- 一般人群结直肠癌风险男性6.6%、女性4.7%,子宫内膜癌2.4%。
临床怎么用
- PMS2特异性筛查方案可仅限于结肠镜检查。
- PMS2携带者行降低风险子宫切除术和双侧输卵管卵巢切除术的作用尚需进一步讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Lynch syndrome due to pathogenic variants in the DNA mismatch repair genes MLH1, MSH2, and MSH6 is predominantly associated with colorectal and endometrial cancer, although extracolonic cancers have been described within the Lynch tumor spectrum. However, the age-specific cumulative risk (penetrance) of these cancers is still poorly defined for PMS2-associated Lynch syndrome. Using a large data set from a worldwide collaboration, our aim was to determine accurate penetrance measures of cancers for carriers of heterozygous pathogenic PMS2 variants. METHODS: A modified segregation analysis was conducted that incorporated both genotyped and nongenotyped relatives, with conditioning for ascertainment to estimates corrected for bias. Hazard ratios (HRs) and corresponding 95% CIs were estimated for each cancer site for mutation carriers compared with the general population, followed by estimation of penetrance. RESULTS: In total, 284 families consisting of 4,878 first- and second-degree family members were included in the analysis. PMS2 mutation carriers were at increased risk for colorectal cancer (cumulative risk to age 80 years of 13% [95% CI, 7.9% to 22%] for males and 12% [95% CI, 6.7% to 21%] for females) and endometrial cancer (13% [95% CI, 7.0%-24%]), compared with the general population (6.6%, 4.7%, and 2.4%, respectively). There was no clear evidence of an increased risk of ovarian, gastric, hepatobiliary, bladder, renal, brain, breast, prostate, or small bowel cancer. CONCLUSION: Heterozygous PMS2 mutation carriers were at small increased risk for colorectal and endometrial cancer but not for any other Lynch syndrome-associated cancer. This finding justifies that PMS2-specific screening protocols could be restricted to colonoscopies. The role of risk-reducing hysterectomy and bilateral salpingo-oophorectomy for PMS2 mutation carriers needs further discussion.
引用
- Ten Broeke SW, van der Klift HM, Tops CMJ, et al. Cancer Risks for PMS2-Associated Lynch Syndrome. J Clin Oncol. 2018. PMID: 30161022. doi:10.1200/JCO.2018.78.4777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。